Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 85

1.

Association of Cognitive Impairment in Patients on 3-Hydroxy-3-Methyl-Glutaryl-CoA Reductase Inhibitors.

Roy S, Weinstock JL, Ishino AS, Benites JF, Pop SR, Perez CD, Gumbs EA, Rosenbaum JA, Roccato MK, Shah H, Contino G, Hunter K.

J Clin Med Res. 2017 Jul;9(7):638-649. doi: 10.14740/jocmr3066w. Epub 2017 May 22.

2.

Clinical Implications of Switching Lipid Lowering Treatment from Rosuvastatin to Other Agents in Primary Care.

Colivicchi F, Gulizia MM, Franzini L, Imperoli G, Castello L, Aiello A, Ripellino C, Cataldo N.

Adv Ther. 2016 Nov;33(11):2049-2058. Epub 2016 Sep 26.

3.

Endothelial lipase genetic polymorphisms and the lipid-lowering response in patients with coronary artery disease on rosuvastatin.

Cai G, Zhang B, Shi G, Weng W, Yang L, Xue S.

Lipids Health Dis. 2016 Sep 6;15(1):148. doi: 10.1186/s12944-016-0295-3.

4.

Statin-associated muscle symptoms and SLCO1B1 rs4149056 genotype in patients with familial hypercholesterolemia.

Khine H, Yuet WC, Adams-Huet B, Ahmad Z.

Am Heart J. 2016 Sep;179:1-9. doi: 10.1016/j.ahj.2016.05.015. Epub 2016 Jun 9.

5.

Efficacy and safety of fixed-dose combination therapy with olmesartan medoxomil and rosuvastatin in Korean patients with mild to moderate hypertension and dyslipidemia: an 8-week, multicenter, randomized, double-blind, factorial-design study (OLSTA-D RCT: OLmesartan rosuvaSTAtin from Daewoong).

Park JS, Shin JH, Hong TJ, Seo HS, Shim WJ, Baek SH, Jeong JO, Ahn Y, Kang WC, Kim YH, Kim SH, Hyon MS, Choi DH, Nam CW, Park TH, Lee SC, Kim HS.

Drug Des Devel Ther. 2016 Aug 16;10:2599-609. doi: 10.2147/DDDT.S112873. eCollection 2016.

6.

Sustained Improvement of Arterial Stiffness and Blood Pressure after Long-Term Rosuvastatin Treatment in Patients with Inflammatory Joint Diseases: Results from the RORA-AS Study.

Ikdahl E, Rollefstad S, Hisdal J, Olsen IC, Pedersen TR, Kvien TK, Semb AG.

PLoS One. 2016 Apr 19;11(4):e0153440. doi: 10.1371/journal.pone.0153440. eCollection 2016.

7.

The Effect of Rosuvastatin on Markers of Immune Activation in Treatment-Naive Human Immunodeficiency Virus-Patients.

Weijma RG, Vos ER, Ten Oever J, Van Schilfgaarde M, Dijksman LM, Van Der Ven A, Van Den Berk GE, Brinkman K, Frissen JP, Leyte A, Schouten IW, Netea MG, Blok WL.

Open Forum Infect Dis. 2015 Dec 23;3(1):ofv201. doi: 10.1093/ofid/ofv201. eCollection 2016 Jan.

9.

The association of HDL-apoCIII with coronary heart disease and the effect of statin treatment on it.

Xiong X, Liu H, Hua L, Zhao H, Wang D, Li Y.

Lipids Health Dis. 2015 Oct 9;14:127. doi: 10.1186/s12944-015-0129-8.

10.

Atherogenic Lipoprotein Subfractions Determined by Ion Mobility and First Cardiovascular Events After Random Allocation to High-Intensity Statin or Placebo: The Justification for the Use of Statins in Prevention: An Intervention Trial Evaluating Rosuvastatin (JUPITER) Trial.

Mora S, Caulfield MP, Wohlgemuth J, Chen Z, Superko HR, Rowland CM, Glynn RJ, Ridker PM, Krauss RM.

Circulation. 2015 Dec 8;132(23):2220-9. doi: 10.1161/CIRCULATIONAHA.115.016857. Epub 2015 Sep 25.

11.

Achievement of specified lipid and high-sensitivity C-reactive protein levels with two statins in Chinese patients with hypercholesterolaemia.

Ding C, Hu M, Wu YJ, Tomlinson B.

Lipids Health Dis. 2015 Sep 13;14:107. doi: 10.1186/s12944-015-0116-0.

12.

Rosuvastatin Worsens Insulin Resistance in HIV-Infected Adults on Antiretroviral Therapy.

Erlandson KM, Jiang Y, Debanne SM, McComsey GA.

Clin Infect Dis. 2015 Nov 15;61(10):1566-72. doi: 10.1093/cid/civ554. Epub 2015 Jul 8.

13.

Doctors' knowledge, attitudes, and compliance with 2013 ACC/AHA guidelines for prevention of atherosclerotic cardiovascular disease in Singapore.

Setia S, Fung SS, Waters DD.

Vasc Health Risk Manag. 2015 Jun 4;11:303-10. doi: 10.2147/VHRM.S82710. eCollection 2015.

14.

Alirocumab as Add-On to Atorvastatin Versus Other Lipid Treatment Strategies: ODYSSEY OPTIONS I Randomized Trial.

Bays H, Gaudet D, Weiss R, Ruiz JL, Watts GF, Gouni-Berthold I, Robinson J, Zhao J, Hanotin C, Donahue S.

J Clin Endocrinol Metab. 2015 Aug;100(8):3140-8. doi: 10.1210/jc.2015-1520. Epub 2015 Jun 1.

15.

The difference between Asian and Western in the effect of LDL-C lowering therapy on coronary atherosclerotic plaque: a meta-analysis report.

Li YF, Feng QZ, Gao WQ, Zhang XJ, Huang Y, Chen YD.

BMC Cardiovasc Disord. 2015 Feb 14;15:6. doi: 10.1186/1471-2261-15-6. Review.

16.

Monascus purpureus-fermented Thai glutinous rice reduces blood and hepatic cholesterol and hepatic steatosis concentrations in diet-induced hypercholesterolemic rats.

Bunnoy A, Saenphet K, Lumyong S, Saenphet S, Chomdej S.

BMC Complement Altern Med. 2015 Mar 28;15:88. doi: 10.1186/s12906-015-0624-5.

17.

Combination therapy analysis of ezetimibe and statins in Chinese patients with acute coronary syndrome and type 2 diabetes.

Li L, Zhang M, Su F, Li Y, Shen Y, Shen J, Zhang D.

Lipids Health Dis. 2015 Feb 18;14:10. doi: 10.1186/s12944-015-0004-7.

18.

High-sensitivity cardiac troponin I and B-type natriuretic Peptide as predictors of vascular events in primary prevention: impact of statin therapy.

Everett BM, Zeller T, Glynn RJ, Ridker PM, Blankenberg S.

Circulation. 2015 May 26;131(21):1851-60. doi: 10.1161/CIRCULATIONAHA.114.014522. Epub 2015 Mar 30.

19.

The hypolipidemic and pleiotropic effects of rosuvastatin are not enhanced by its association with zinc and selenium supplementation in coronary artery disease patients: a double blind randomized controlled study.

Sena-Evangelista KC, Pedrosa LF, Paiva MS, Dias PC, Ferreira DQ, Cozzolino SM, Faulin TE, Abdalla DS.

PLoS One. 2015 Mar 18;10(3):e0119830. doi: 10.1371/journal.pone.0119830. eCollection 2015.

20.

Low rates of both lipid-lowering therapy use and achievement of low-density lipoprotein cholesterol targets in individuals at high-risk for cardiovascular disease across Europe.

Halcox JP, Tubach F, Lopez-Garcia E, De Backer G, Borghi C, Dallongeville J, Guallar E, Medina J, Perk J, Sazova O, Sweet S, Roy C, Banegas JR, Rodriguez-Artalejo F.

PLoS One. 2015 Feb 18;10(2):e0115270. doi: 10.1371/journal.pone.0115270. eCollection 2015.

Supplemental Content

Loading ...
Support Center